Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-357-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.99 million
Profitability
Miscellaneous
Employees167
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
How were Ocular Therapeutix's earnings last quarter?
Ocular Therapeutix Inc (NASDAQ:OCUL) issued its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.15. The biopharmaceutical company earned $0.65 million during the quarter, compared to analyst estimates of $1 million. Ocular Therapeutix had a negative net margin of 3,450.84% and a negative return on equity of 256.69%. View Ocular Therapeutix's Earnings History.
When is Ocular Therapeutix's next earnings date?
What price target have analysts set for OCUL?
6 analysts have issued 1-year price targets for Ocular Therapeutix's stock. Their forecasts range from $3.00 to $24.00. On average, they anticipate Ocular Therapeutix's stock price to reach $9.67 in the next year. This suggests a possible upside of 173.1% from the stock's current price. View Analyst Price Targets for Ocular Therapeutix.
What is the consensus analysts' recommendation for Ocular Therapeutix?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ocular Therapeutix.
Has Ocular Therapeutix been receiving favorable news coverage?
News coverage about OCUL stock has trended negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Ocular Therapeutix earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Ocular Therapeutix.
Are investors shorting Ocular Therapeutix?
Ocular Therapeutix saw a decline in short interest in September. As of September 30th, there was short interest totalling 5,990,000 shares, a decline of 6.3% from the August 30th total of 6,390,000 shares. Based on an average daily volume of 595,300 shares, the days-to-cover ratio is currently 10.1 days. Currently, 14.7% of the shares of the company are short sold. View Ocular Therapeutix's Current Options Chain.
Who are some of Ocular Therapeutix's key competitors?
Some companies that are related to Ocular Therapeutix include ZIOPHARM Oncology (ZIOP), Vectura Group (VEGPF), NextCure (NXTC), Akero Therapeutics (AKRO), Akorn (AKRX), Advanz Pharma (CXRXF), Homology Medicines (FIXX), DiaMedica Therapeutics (DMCAF), Catalyst Pharmaceuticals (CPRX), MacroGenics (MGNX), OrganiGram (OGI), IGM Biosciences (IGMS), Flexion Therapeutics (FLXN), TG Therapeutics (TGTX) and Arvinas (ARVN).
What other stocks do shareholders of Ocular Therapeutix own?
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the folowing people:
- Mr. Antony Mattessich, Pres, CEO & Director (Age 52)
- Mr. Donald Notman Jr., Chief Financial Officer
- Dr. Michael H. Goldstein, Chief Medical Officer (Age 52)
- Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 57)
- Dr. Peter K. Jarrett Ph.D., Chief Scientific Officer (Age 62)
How do I buy shares of Ocular Therapeutix?
Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ocular Therapeutix's stock price today?
One share of OCUL stock can currently be purchased for approximately $3.54.
How big of a company is Ocular Therapeutix?
Ocular Therapeutix has a market capitalization of $167.09 million and generates $1.99 million in revenue each year. The biopharmaceutical company earns $-59,980,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Ocular Therapeutix employs 167 workers across the globe.View Additional Information About Ocular Therapeutix.
What is Ocular Therapeutix's official website?
How can I contact Ocular Therapeutix?
Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]
MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.
